Skip to main content
. 2012 Apr 9;7(4):e34321. doi: 10.1371/journal.pone.0034321

Figure 2. Exploration the potential of hBMMSC-iPSCs into CD34+ progenitor cells with the defined factors.

Figure 2

(A) Schematic of CD34+ progenitor cell differentiation protocol for the study. (B) Protocol for the chosen defined factors, divided into groups according to their function, to direct hBMMSC-iPSCs to CD34+ progenitor cells, and then to hematopoietic and endothelial cells. (C-D) Enhanced expression of mesoderm transcription factor Brachyury and GATA-2 was detected in factor-treated hBMMSC-iPSCs, compared to the spontaneous differentiation groups by RT-PCR (C) and fluorescence intensity (D) assay after the differentiation for 5 days. The values were the mean ± SD of 3 independent experiments. (E) Immunoassay revealed that the hematopoietic transcription factor GATA-2 was up-regulated after factor treatment for 5 days and it was more efficient in hBMMSC-iPSC groups treated with the factors than in the spontaneous groups (control). The expression of the plutipotent marker Oct4 was similar between two groups. Scale bar, 100 µm.